Publication | Open Access

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

Health-related Quality-of-life ResultsSurgical OncologyOncologyMelanomaImmunologyClinical TrialsImmune Checkpoint InhibitorEortc 1325-Mg/keynote-054Cancer TreatmentImmunotherapyMedicinePhase 3